Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Li, Feng Fei ^a   Gao, Gu ^a   Li, Qian ^a   Zhu, Hong Hong ^a   Su, Xiao Fei ^a   Wu, Jin Dan ^a   Ye, Lei ^b   Ma, Jian Hua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ANTIDIABETIC AGENT; DAPAGLIFLOZIN; GLUCOSE; METFORMIN; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 8-EPI-PROSTAGLANDIN F2ALPHA; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PROSTAGLANDIN F2 ALPHA;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DATA COLLECTION METHOD; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATIENT COUNSELING; PHASE 3 CLINICAL TRIAL; PLASMA; PROSTAGLANDIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK REDUCTION; TREATMENT DURATION; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; METABOLISM;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DINOPROST; DOUBLE-BLIND METHOD; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; OXIDATIVE STRESS;

EID: 84990987756     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/5347262     Document Type: Article

References (38)

1. M. A. Abdul-Ghani and R. A. Defronzo, "Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport, " Journal of Internal Medicine, vol. 276, no. 4, pp. 352-363, 2014.
2. E. Ferrannini and A. Solini, "SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects, " Nature Reviews Endocrinology, vol. 8, no. 8, pp. 495-502, 2012.
3. C. J. Bailey, E. C. Morales Villegas, V. Woo, W. Tang, A. Ptaszynska, and J. F. List, "Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial, " Diabetic Medicine, vol. 32, no. 4, pp. 531-541, 2015.
4. J. P. H. Wilding, V. Woo, K. Rohwedder, J. Sugg, and S. Parikh, "Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years, " Diabetes, Obesity and Metabolism, vol. 16, no. 2, pp. 124-136, 2014.
5. M. A. Nauck, S. DelPrato, J. J. Meier et al., "Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial, " Diabetes Care, vol. 34, no. 9, pp. 2015-2022, 2011.
6. W. T. Cefalu, L. A. Leiter, T. W. A. De Bruin, I. Gause-Nilsson, J. Sugg, and S. J. Parikh, "Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension, " Diabetes Care, vol. 38, no. 7, pp. 1218-1227, 2015.
7. H. J. Lambers Heerspink, D. De Zeeuw, L. Wie, B. Leslie, and J. List, "Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes, " Diabetes, Obesity and Metabolism, vol. 15, no. 9, pp. 853-862, 2013.
8. K. Strojek, K.-H. Yoon, V. Hruba, J. Sugg, A. M. Langkilde, and S. Parikh, "Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial, " DiabetesTherapy, vol. 5, no. 1, pp. 267-283, 2014.
9. L. A. Leiter, W. T. Cefalu, T. W. de Bruin et al., "Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease, " Diabetes, Obesity &Metabolism, vol. 18, no. 8, pp. 766-774, 2016.
10. S. Del Prato, M. Nauck, S. Durán-Garcia et al., "Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data, " Diabetes, Obesity & Metabolism, vol. 17, no. 6, pp. 581-590, 2015.
11. L. A. Leiter, W. T. Cefalu, T. W. A. de Bruin, I. Gause-Nilsson, J. Sugg, and S. J. Parikh, "Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension, " Journal of the American Geriatrics Society, vol. 62, no. 7, pp. 1252-1262, 2014.
12. K. T. Nathan, N. Ahmed-Sarwar, and P. Werner, "SGLT-2 inhibitors: a novel mechanism in targeting glycemic control in type 2 diabetesmellitus, " The Consultant Pharmacist, vol. 31, no. 5, pp. 251-260, 2016.
13. Y. Wang, L. Xu, L. Yuan et al., "Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes, " Diabetic Medicine, 2016.
14. TheDiabetes Control and Complications Trial Research Group, "The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial, " Diabetes, vol. 44, no. 8, pp. 968-983, 1995.
15. R. Klein, "Hyperglycemia and microvascular and macrovascular disease in diabetes, " Diabetes Care, vol. 18, no. 2, pp. 258-268, 1995.
16. I. M. Stratton, A. I. Adler, H. A. W. Neil et al., "Associationof glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): ProspectiveObservational Study, " British Medical Journal, vol. 321, no. 7258, pp. 405-412, 2000.
17. L. Monnier, E. Mas, C. Ginet et al., "Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes, " The Journal of the AmericanMedical Association, vol. 295, no. 14, pp. 1681-1687, 2006.
18. Y. Hu, W. Liu, R. Huang, and X. Zhang, "Postchallenge plasma glucose excursions, carotid intima-media thickness, and risk factors for atherosclerosis in Chinese population with type 2 diabetes, " Atherosclerosis, vol. 210, no. 1, pp. 302-306, 2010.
19. G. Santulli, G. Pagano, C. Sardu et al., "Calcium release channel RyR2 regulates insulin release and glucose homeostasis, " The Journal of Clinical Investigation, vol. 125, no. 5, pp. 1968-1978, 2015.
20. J. Zhou, H. Li, X. Ran et al., "Reference values for continuous glucose monitoring in Chinese subjects, " Diabetes Care, vol. 32, no. 7, pp. 1188-1193, 2009.
21. F.-F. Li, X.-H. Xu, L.-Y. Fu et al., "Influence of acarbose on plasma glucose fluctuations in insulin-treated patientswith type 2 diabetes: a pilot study, " International Journal of Endocrinology, vol. 2015, Article ID 903524, 5 pages, 2015.
22. F.-F. Li, L.-Y. Fu, W.-L. Zhang et al., "Blood glucose fluctuations in type 2 diabetes patients treated with multiple daily injections, " Journal of Diabetes Research, vol. 2016, Article ID 1028945, 8 pages, 2016.
23. J.-D. Wu, X.-H. Xu, J. Zhu et al., "Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetesmellitus, " Diabetes Technology&Therapeutics, vol. 13, no. 2, pp. 143-148, 2011.
24. F. Zaccardi, D. R. Webb, Z. Z. Htike, D. Youssef, K. Khunti, and M. J. Davies, "Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis, " Diabetes, Obesity and Metabolism, vol. 18, no. 8, pp. 783-794, 2016.
25. A. Ceriello, K. Esposito, L. Piconi et al., "Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients, " Diabetes, vol. 57, no. 5, pp. 1349-1354, 2008.
26. B. Gallwitz, "Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines, " Diabetes care, vol. 32, supplement 2, pp. S322-S325, 2009.
27. T. Nakagami, "Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin, " Diabetologia, vol. 47, no. 3, pp. 385-394, 2004.
28. A. Ceriello, L. Quagliaro, B. Catone et al., "Role of hyperglycemia in nitrotyrosine postprandial generation, " Diabetes Care, vol. 25, no. 8, pp. 1439-1443, 2002.
29. H. C. Gerstein, "The plasma glucose level-a continuous risk factor for vascular disease in both diabetic and non-diabetic people, " in Diabetes and Cardiovascular Disease, vol. 498 of Advances in Experimental Medicine and Biology, pp. 35-39, Springer, 2001.
30. E. Selvin, S. Marinopoulos, G. Berkenblit et al., "Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus, "Annals of InternalMedicine, vol. 141, no. 6, pp. 421-431, 2004.
31. C. Sardu, R. Marfella, and G. Santulli, "Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people, " Journal of Cardiovascular Translational Research, vol. 7, no. 3, pp. 362-368, 2014.
32. C. Sardu, M. Barbieri, M. R. Rizzo, P. Paolisso, G. Paolisso, and R. Marfella, "Cardiac resynchronization therapy outcomes in type 2 diabetic patients: role of microRNA changes, " Journal of Diabetes Research, vol. 2016, Article ID 7292564, 8 pages, 2016.
33. R. Marfella, M. R. Rizzo, M. Siniscalchi et al., "Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevationmyocardial infarction: effects on myocardial salvage, " International Journal of Cardiology, vol. 168, no. 4, pp. 3954-3962, 2013.
34. M. L. Balestrieri, M. R. Rizzo, M. Barbieri et al., "Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment, " Diabetes, vol. 64, no. 5, pp. 1395-1406, 2015.
35. M. Barbieri, M. R. Rizzo, I. Fava et al., "Awaking blood pressure surge and progression to microalbuminuria in type 2 normotensive diabetic patients, " Journal of Diabetes Research, vol. 2016, Article ID 5876792, 6 pages, 2016.
36. M. R. Rizzo, F. C. Sasso, R. Marfella et al., "Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes, " Journal ofDiabetes and Its Complications, vol. 29, no. 1, pp. 88-92, 2015.
37. R. Marfella, F. C. Sasso, M. Siniscalchi et al., "Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients, " Journal of the American College of Cardiology, vol. 62, no. 6, pp. 525-530, 2013.
38. C. Sardu, G. Carreras, S. Katsanos et al., "Metabolic syndrome is associated with a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation, " BMC Cardiovascular Disorders, vol. 14, no. 1, article 176, 2014.